PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Emerging Anti-Obesity Targets Extend Beyond Incretin Pharmacotherapy

semaglutidetirzepatideretatrutideorforglipronmazdutidemaridebart cafraglutidebimagrumabcagrilintideGLP-1 receptor agonistGIPglucagonamylin analogFGF21obesityanti-obesity pharmacotherapynarrative reviewdrug pipeline Endocrinology / Diabetes / Obesity

Background Information

Innovative anti-obesity drugs offer hope beyond current treatments.

Obesity is a growing global issue with current treatments presenting challenges like adverse effects and rebound weight gain, highlighting the need for new therapies. The review identifies potential non-incretin pharmacological targets and novel anti-obesity drug candidates for further clinical validation. While promising, these emerging therapies require more clinical trials to assess their safety and efficacy compared to current options before influencing practice. New non-incretin anti-obesity drugs are on the horizon, offering hope for safer, more effective treatments.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Lee S, Song H, Kwon Y

Citation: Lee S, Song H, Kwon Y A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy. Pharmaceuticals (Basel, Switzerland). 2026;19(7). doi:10.3390/ph19071047

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.